ERBB2 and neoplasm: These results further indicated that LCB‐ADCs displayed an efficient anticancer effect in HER2‐expressing tumors even at a low level of HER2, and strongly suggest that the intended advantages of LCB‐ADCs, such as increased linker stability in the bloodstream, an accurate DAR and reliable homogeneity, and an improved PK profile can be observed in xenograft tumor models.